On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a $1 trillion valuation teaming up with a tech firm that has ridden the AI wave to a record-setting $5 trillion valuation of its own—a Wall Street supergroup, a la Cream, Audioslave or boygenius.
A handful of pharmas and celebrities are joining forces with the National Bleeding Disorders Foundation for a long-lasting awareness push.
While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with a positive recommendation from the CHMP.
Two years and five indications later, UCB's immunology blockbuster Bimzelx is halfway to the company's initial goal of at least 4 billion euros ($4.4 billion) in peak sales.
As one long-running feud over the controversial generic drug carve-out known as “skinny” labeling comes to a close, the U.S.’ top lawyer is urging the Supreme Court to reverse a recent decision on another, arguing the ruling undermines a critical U.S. pathway for copycat medicines enshrined by Congress.
It’s high time to focus on sexual and reproductive health for men.
A genetic test to diagnose ALS. Dental floss that can track your cortisol levels. Check out the 64 innovations and discoveries in our annual STAT Madness bracket.
He’s an action figure. He’s a milk-drinking rave-goer. He’s America’s health secretary.
For too long, the promise of personalized therapies has been tantalizingly close, yet frustratingly out of reach for rare-disease families.
China assets have outgrown a “bargain basement” label as the upfront value of licensing deals involving them has increased, Evaluate said. Daiichi Sankyo named former Novartis exec John Tsai, M.D., as its new R&D head. Astellas is committing up to $1.7 billion to partner on Vir Biotechnology's PSMA-targeting T-cell engager. And more.
Fierce Pharma's Angus Liu speaks with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former FDA oncology division director, about a recent article from agency officials outlining how the FDA plans to regulate CAR-T therapies in autoimmune diseases and what its case-by-case approach could mean for drug developers.
Heart disease is on track to tighten its grip on American women. New projections from the American Heart Association warn that over the next 25 years, cardiovascular disease will rise sharply, driven largely by a surge in high blood pressure, diabetes, and obesity. By 2050, nearly 60% of women in the U.S. could have high blood pressure, and close to one in three women ages 22 to 44 may already be
DOJ is backing AbbVie in its battle to overturn a Colorado law that prohibits pharmaceutical companies from placing restrictions on the 340B drug discount program.
Scoop: Cigna has acquired CarepathRx, a large pharmacy backed by private equity that dispenses prescription drugs to nearly 10% of U.S. hospitals.
Patients and caregivers share their perspectives on their clinical trial experiences to help industry with future trial optimization and accessibility.
This webinar addresses how pharmaceutical organizations are expanding their clinical trial operations globally to support evolving portfolios and react to geopolitics.
In this webinar, which is a rebroadcast from the 2025 PODD Conference, business development and technology assessment professionals actively involved in the scouting and evaluating of novel delivery technologies, discuss the constantly evolving topic of partnering.
On this week's Readout LOUD: Adam is joined by guest host Jared Holz to talk M&A, FDA turmoil, election intrigue, and more.
The Trump administration issued a nationwide moratorium on new suppliers for certain medical equipment, citing fraud.
This week on STATus Report, everything you need to know about RFK Jr., MAHA, and "glypho-gate."